LT3610875T - Opioido (mor) agonisto druska, jo fumarato druskos i kristalinė forma ir jos gavimo būdas - Google Patents

Opioido (mor) agonisto druska, jo fumarato druskos i kristalinė forma ir jos gavimo būdas

Info

Publication number
LT3610875T
LT3610875T LTEP18784878.3T LT18784878T LT3610875T LT 3610875 T LT3610875 T LT 3610875T LT 18784878 T LT18784878 T LT 18784878T LT 3610875 T LT3610875 T LT 3610875T
Authority
LT
Lithuania
Prior art keywords
salt
mor
opioid
preparation
crystal form
Prior art date
Application number
LTEP18784878.3T
Other languages
English (en)
Inventor
Lin Wang
Likun WANG
Original Assignee
Jiangsu Hengrui Medicine Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co., Ltd. filed Critical Jiangsu Hengrui Medicine Co., Ltd.
Publication of LT3610875T publication Critical patent/LT3610875T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP18784878.3T 2017-04-14 2018-04-13 Opioido (mor) agonisto druska, jo fumarato druskos i kristalinė forma ir jos gavimo būdas LT3610875T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710242119 2017-04-14
PCT/CN2018/082935 WO2018188643A1 (zh) 2017-04-14 2018-04-13 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法

Publications (1)

Publication Number Publication Date
LT3610875T true LT3610875T (lt) 2020-11-25

Family

ID=63792318

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP18784878.3T LT3610875T (lt) 2017-04-14 2018-04-13 Opioido (mor) agonisto druska, jo fumarato druskos i kristalinė forma ir jos gavimo būdas

Country Status (23)

Country Link
US (2) US11014914B2 (lt)
EP (1) EP3610875B1 (lt)
JP (1) JP7153030B6 (lt)
KR (1) KR20190140962A (lt)
CN (1) CN110049980B (lt)
AU (1) AU2018251119B2 (lt)
BR (1) BR112019021447A2 (lt)
CA (1) CA3057383A1 (lt)
CY (1) CY1124063T1 (lt)
DK (1) DK3610875T3 (lt)
ES (1) ES2828636T3 (lt)
HR (1) HRP20210022T1 (lt)
HU (1) HUE053244T2 (lt)
LT (1) LT3610875T (lt)
MX (1) MX383989B (lt)
MY (1) MY196571A (lt)
PL (1) PL3610875T3 (lt)
PT (1) PT3610875T (lt)
RS (1) RS61193B1 (lt)
SI (1) SI3610875T1 (lt)
TW (1) TWI682929B (lt)
UA (1) UA124400C2 (lt)
WO (1) WO2018188643A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018188643A1 (zh) * 2017-04-14 2018-10-18 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法
AU2018251118A1 (en) * 2017-04-14 2019-10-17 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing MOR agonist and KOR agonist, and uses thereof
WO2019205983A1 (zh) * 2018-04-28 2019-10-31 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途
CN112638907B (zh) * 2018-10-12 2022-04-12 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN112638906B (zh) * 2018-10-12 2022-05-27 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN111662284B (zh) * 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
KR20210113824A (ko) 2020-03-09 2021-09-17 건국대학교 산학협력단 뮤 오피오이드 수용체의 활성화제를 유효성분으로 포함하는 기분 장애의 예방용 조성물
CN117529481B (zh) * 2021-07-13 2026-03-03 上海海雁医药科技有限公司 Mor受体激动剂的药学上可接受的盐、其多晶型物及其用途
CN117624138A (zh) * 2022-08-29 2024-03-01 江苏恒瑞医药股份有限公司 一种氧杂螺环类衍生物的可药用盐、晶型及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700325T1 (it) 2011-03-23 2017-09-07 Trevena Inc Ligandi del recettore degli oppioidi e metodi per l’uso e la produzione dei medesimi
KR102703513B1 (ko) 2015-10-15 2024-09-06 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 옥사 스파이로 유도체, 이의 제조방법, 및 의약에서 이의 응용
WO2018188643A1 (zh) * 2017-04-14 2018-10-18 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法

Also Published As

Publication number Publication date
ES2828636T3 (es) 2021-05-27
BR112019021447A2 (pt) 2020-05-05
AU2018251119B2 (en) 2021-07-29
JP7153030B2 (ja) 2022-10-13
CA3057383A1 (en) 2018-10-18
PT3610875T (pt) 2020-11-25
UA124400C2 (uk) 2021-09-08
SI3610875T1 (sl) 2021-02-26
HUE053244T2 (hu) 2021-06-28
PL3610875T3 (pl) 2021-04-19
WO2018188643A1 (zh) 2018-10-18
EP3610875A1 (en) 2020-02-19
TWI682929B (zh) 2020-01-21
HRP20210022T1 (hr) 2021-03-05
TW201837033A (zh) 2018-10-16
EP3610875A4 (en) 2020-02-19
US11014914B2 (en) 2021-05-25
EP3610875B1 (en) 2020-10-07
AU2018251119A1 (en) 2019-11-07
RS61193B1 (sr) 2021-01-29
JP7153030B6 (ja) 2023-07-24
MX383989B (es) 2025-03-14
RU2019136088A (ru) 2021-05-14
DK3610875T3 (da) 2020-12-21
KR20190140962A (ko) 2019-12-20
MX2019012251A (es) 2019-11-28
JP2020516642A (ja) 2020-06-11
CN110049980A (zh) 2019-07-23
US20200048229A1 (en) 2020-02-13
MY196571A (en) 2023-04-19
US20210130332A1 (en) 2021-05-06
CN110049980B (zh) 2020-10-20
RU2019136088A3 (lt) 2021-06-16
CY1124063T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
IL265730A (en) Crystalline forms and salts of ppar agonist compounds
DK2970123T4 (da) Krystallinsk dihydrochloridhydratsalt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf
PL3610875T3 (pl) Sól agonisty receptora opioidowego (MOR), postać krystaliczna I jego soli fumaranowej i sposób jej wytwarzania
EP2982675A4 (en) SALT OF A PYRAZOLOCHINOLINE DERIVATIVE AND CRYSTAL THEREOF
LT3514151T (lt) Proteinkinazės c inhibitoriai ir jų naudojimo būdai
LT3490988T (lt) Naujas junginys ir gavimo būdas
DK3412674T3 (da) Trifluoracetatsalt af en TLR7-agonist og krystalform B deraf, fremstillingsfremgangsmåder og anvendelser
HUE059605T2 (hu) TLR agonista tartalmú készítmény és használati eljárások
LT3012255T (lt) Stabili tipiracilo hidrochlorido kristalinė forma ir jo kristalizacijos būdas
IL260965B (en) The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures
IL269626A (en) Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
LT3255046T (lt) Nuo ciklino priklausančio baltymo kinazės inhibitoriaus hidroksietilo sulfonatas, jo kristalinė forma ir jos gavimo būdas
ZA201903769B (en) L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
LT3331516T (lt) Ropivakaino hidrochlorido hiperbarinis injekcinis tirpalas ir jo paruošimo procesas
LT3309149T (lt) 6-brom-3-hidroksi-2-pirazinkarboksamido kristalas ir jo gamybos būdas
LT3327012T (lt) Bilastino kristalinės formos ir jų gamybos būdai
EP3505516A4 (en) QUINAZOLINE DERIVATIVE SALT CRYSTAL
PL3330267T3 (pl) Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształu
IL251405B (en) Crystalline forms of pemetrexed diacid and manufacturing processes therefor
EP3269710A4 (en) Nintedanib diethanesulfonate salt crystal and preparation method and use thereof
LT3190115T (lt) Cefalosporino darinio druska, jos kristalinė kietoji forma ir gamybos būdas
IL246835A0 (en) Improved process for the preparation of trazodone and its hydrochloride salt
IL263771A (en) Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof
SI2941271T1 (sl) C-terminalni zaviralci HSP90 za zdravljenje adenomov hipofize
TH1501002154A (th) สารละลายเพื่อการทำความสะอาด, สิ่งอำนวยความสะดวกเพื่อการทำความสะอาด และวิธีการของการทำความสะอาด ซับสเตรตของเครื่องยึด